Zymeworks, Inc. (ZYME)
29.61
-1.44
(-4.64%)
USD |
NASDAQ |
Sep 03, 15:44
Zymeworks Research and Development Expense (Annual) : 137.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 137.00M |
| December 31, 2024 | 134.62M |
| December 31, 2023 | 143.62M |
| December 31, 2022 | 208.60M |
| December 31, 2021 | 199.75M |
| December 31, 2020 | 168.53M |
| Date | Value |
|---|---|
| December 31, 2019 | 115.90M |
| December 31, 2018 | 56.93M |
| December 31, 2017 | 40.67M |
| December 31, 2016 | 35.55M |
| December 31, 2015 | 24.40M |
| December 31, 2014 | 10.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Theravance Biopharma, Inc. | 35.91M |
| BridgeBio Pharma, Inc. | 451.95M |
| Aprea Therapeutics, Inc. | 7.043M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |